18 F-FLT and FF-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models

International Journal of Radiation Biology

Volumn 85, Issue 9, 2009, Pages 763-771

  Debucquoy, Annelies ^a   Devos, Ellen ^b   Vermaelen, Peter ^b   Landuyt, Willy ^a   De Weer, Stefanie ^a   Van Den Heuvel, Frank ^a   Haustermans, Karin ^a  

^a Department of Radiation Oncology and Experimental Therapy ^*  (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Colorectal carcinoma cells; COX 2; Imaging; In vivo PET; Radiosensitizers; Xenografts

Indexed keywords

3' FLUOROTHYMIDINE F 18; CELECOXIB; CYCLOOXYGENASE 2; FLUORODEOXYGLUCOSE F 18; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; CYCLOOXYGENASE 2 INHIBITOR; DIAGNOSTIC AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LINEAR ACCELERATOR; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIZATION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; COLORECTAL TUMOR; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; SCINTISCANNING; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70249127555     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000903072074     Document Type: Article

References (31)

1. Bading JR, Shields AF. 2008. Imaging of cell proliferation: status and prospects. Journal of Nuclear Medicine 49(Suppl. 2): 64-80.
2. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, Luthra SK, Brady F, Price PM, Aboagye EO. 2003. 30-deoxy-30-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Research 63(13):3791-3798.
3. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK. 2001. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. International Journal of Cancer 91(6):894-899.
4. Chinery R, Coffey RJ, Graves-Deal R, Kirkland SC, Sanchez SC, Zackert WE, Oates JA, Morrow JD. 1999. Prostaglandin J2 and 15-deoxy-delta12,14- prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Research 59(11):2739-2746.
5. Davis TW, O'Neal JM, Pagel MD, Zweifel BS, Mehta PP, Heuvelman DM, Masferrer JL. 2004. Synergy between celecoxib and radiotherapy results from inhibition of cycloox-ygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Research 64(1):279-285.
6. Diaz A, Chepenik KP, Korn JH, Reginato AM, Jimenez SA. 1998. Differential regulation of cyclooxygenases 1 and 2 by inter-leukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Experimental Cell Research 241(1):222-229.
7. Dittmann KH, Mayer C, Ohneseit PA, Raju U, Andratschke NH, Milas L, Rodemann HP. 2008. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: A COX-2 independent mechanism. International Journal of Radiation Oncology Biology Physics 70(1):203-212.
8. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. 2006. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of National Cancer Institute 98(11):736-747.
9. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, Evans J, O'Neill G. 1996. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111(2): 445-454.
10. Khan KN, Masferrer JL, Woerner BM, Soslow R, Koki AT. 2001. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scandinavion Journal of Gastroenterol 36(8):865-869.
11. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, Tofilon PJ, Milas L. 2000. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Research 60(5):1326-1331. (Pubitemid 30152002)
12. Leahy KM, Koki AT, Masferrer JL. 2000. Role of cyclooxygenases in angiogenesis. Current Medicinal Chemistry 7(11): 1163-1170.
13. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. 2002. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Research 62(3):625-631.
14. Leyton J, Alao JP, Da CM, Stavropoulou AV, Latigo JR, Perumal M, Pillai R, He Q, Atadja P, Lam EW, Workman P, Vigushin DM, Aboagye EO. 2006. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 30-deoxy-30-[18F]fluorothymidine positron emission tomography. Cancer Research 66(15): 7621-7629.
15. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. 2005. Early detection of tumor response to chemotherapy by 30-deoxy-30-[18F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Research 65(10):4202-4210.
16. Li G, Yang T, Yan J. 2002. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochemical and Biophysical Research Communications 299(5):886-890.
17. Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, Krohn KA. 2007. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeox-yglucose and beyond. Clinical Cancer Research 13(12): 3460-3469.
18. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN. 2001. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120(7):1713-1719.
19. Milas L. 2001. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Seminars in Radiation Oncology 11(4):290-299.
20. Milas L, Kishi K, Hunter N, Mason K, Masferrer JL, Tofilon PJ. 1999. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. Journal of the National Cancer Institute 91(17):1501-1504.
21. Pyo H, Choy H, Amorino GP, Kim JS, Cao Q, Hercules SK, DuBois RN. 2001. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clinical Cancer Research 7(10):2998-3005.
22. Salskov A, Tammisetti VS, Grierson J, Vesselle H. 2007. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 30-deoxy-30-[18F]fluorothymidine. Seminars in Nuclear Medicine 37(6):429-439.
23. Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN. 2000. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. Journal of Biological Chemistry 275(43): 33951-33956.
24. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. 1998. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Research 58(2): 362-366.
25. Shin YK, Park JS, Kim HS, Jun HJ, Kim GE, Suh CO, Yun YS, Pyo H. 2005. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)- 2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Research 65(20):9501-9509.
26. Sugiyama M, Sakahara H, Sato K, Harada N, Fukumoto D, Kakiuchi T, Hirano T, Kohno E, Tsukada H. 2004. Evaluation of 30-deoxy-30- 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. Journal of Nuclear Medicine 45(10):1754-1758.
27. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. 2002. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Research 62(17):4903-4908.
28. Tazawa R, Xu XM, Wu KK, Wang LH. 1994. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochemical and Biophysical Research Communications 203(1):190-199.
29. Tsujii M, Kawano S, DuBois RN. 1997. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences of the USA 94(7):3336-3340.
30. van Waarde A, Elsinga PH. 2008. Proliferation markers for the differential diagnosis of tumor and inflammation. Current Pharmaceutical Design 14(31):3326-3339.
31. Zhao S, Kuge Y, Kohanawa M, Takahashi T, Zhao Y, Yi M, Kanegae K, Seki K, Tamaki N. 2008. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: A comparison with 18F-FDG and 18F-FLT. Journal of Nuclear Medicine 49(1):135-141.